Review
Gastroenterology & Hepatology
Blake Niccum, Oluwatoba Moninuola, Kaia Miller, Hamed Khalili
Summary: In a systematic review and meta-analysis, it was found that 21% of outpatients with IBD (and 62% of hospitalized patients) are opioid users. Opioid use is associated with more severe IBD and increased healthcare use, suggesting urgent interventions are needed to reduce opioid use and improve disease-related outcomes.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Dickson Kofi Wiredu Ocansey, Sanhua Hang, Xinyi Yuan, Hua Qian, Mengjiao Zhou, Chinasa Valerie Olovo, Xu Zhang, Fei Mao
Summary: The gut microbiome plays a crucial role in integrating environmental inputs, genetics, and immune signals to affect the host's metabolism and immune response. Changes in gut bacteria have been shown to be linked to gastrointestinal conditions such as inflammatory bowel disease (IBD), suggesting the potential for improving IBD diagnosis, prognosis, and treatment through manipulating the gut microbiome. Advancements in sequencing techniques have allowed for a better understanding of the complexity of the gut microbial ecosystem, and current data shows promising results in predicting IBD compared to traditional biomarkers. This study reviews the differential potential of gut bacteria within IBD cohorts and between IBD and other gastrointestinal diseases.
Article
Gastroenterology & Hepatology
Rahul S. Dalal, Sonali Palchaudhuri, Christopher K. Snider, James D. Lewis, Shivan J. Mehta, Gary R. Lichtenstein
Summary: The study found a significant positive correlation between preadmission cannabis use and inpatient opioid exposure among patients with inflammatory bowel disease. Additionally, first patient-reported pain score and preadmission opioid use were also associated with inpatient opioid exposure.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Gastroenterology & Hepatology
Marie Muller, Julien Broseus, Adrien Guilloteau, Stephane Wasse, Catherine Thieblemont, Stephane Nancey, Guillaume Cadiot, Aurelien Amiot, David Laharie, Sophie Vieujean, Yoram Bouhnik, Chloe Martineau, Christophe Michiels, Xavier Hebuterne, Guillaume Savoye, Denis Franchimont, Philippe Seksik, Laurent Beaugerie, Marc Maynadie, Pierre Feugier, Laurent Peyrin-Biroulet
Summary: Inflammatory bowel disease (IBD) is associated with an increased risk of developing lymphoma. However, the clinical and pathological characteristics of lymphoma in IBD patients are poorly understood. A multicentre case-control study found that the prognosis of lymphoma in IBD patients is not worse compared to non-IBD patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Archana Shubhakar, Bas C. Jansen, Alex T. Adams, Karli R. Reiding, Nicholas T. Ventham, Rahul Kalla, Daniel Bergemalm, Paulina A. Urbanowicz, Richard A. Gardner, Manfred IBD BIOM Consortium, Manfred Wuhrer, Jonas Halfvarson, Jack Satsangi, Daryl L. Fernandes, Daniel I. R. Spencer
Summary: This study investigated a composite serum N-glycomic biomarker to predict future disease course in newly diagnosed IBD patients. The biomarker showed a predictive capacity for treatment escalation in both the discovery and replication cohorts of patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Pharmacology & Pharmacy
Rocio Rivera Rodriguez, Jeremy James Johnson
Summary: Inflammatory Bowel Disease (IBD) is a chronic autoimmune disease characterized by intestinal inflammation. The incidence of IBD is rapidly increasing in newly developed countries, making it a global concern. Two major types of IBD, ulcerative colitis (UC) and Crohn's disease (CD), have different manifestations and locations of inflammation in the digestive tract. Current FDA-approved treatments for IBD are only effective for 50% of patients and come with serious side effects, highlighting the need for safer and more effective therapies. Plant-based diets, such as the Mediterranean diet rich in anti-inflammatory phytochemicals, have shown benefits in preventing and improving symptoms of IBD. Terpenes, a class of phytochemicals abundant in Mediterranean herbs and citrus fruits, have been studied for their potential to modulate inflammatory signaling in IBD. However, there is still conflicting and inconclusive evidence regarding their effectiveness. This review evaluates preclinical studies on terpenes and their impact on basic inflammatory signaling in IBD.
PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Gastroenterology & Hepatology
Jessica L. Sheehan, Janson Jacob, Elliot M. Berinstein, LaVana Greene-Higgs, Calen A. Steiner, Sameer K. Berry, Carol Shannon, Shirley A. Cohen-Mekelburg, Peter D. R. Higgins, Jeffrey A. Berinstein
Summary: Pain management in patients with inflammatory bowel disease is challenging due to the potential adverse effects of opioids. This study systematically reviewed the impact of opioid use on healthcare utilization in inflammatory bowel disease patients.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Microbiology
G. Sarrabayrouse, A. Elias, F. Yanez, L. Mayorga, E. Varela, C. Bartoli, F. Casellas, N. Borruel, C. Herrera de Guise, K. Machiels, S. Vermeire, C. Manichanh
Summary: This study utilized fungal and bacterial loads as biomarkers combined with demographic and standard laboratory data to improve the performance of random forest models in diagnosing IBD and predicting CD and UC relapse. Fecal fungal and bacterial load data showed significant differences between healthy relatives of IBD patients and nonrelated healthy controls, as well as between CD and UC patients in different states. These findings suggest that fecal microbial loads could serve as a noninvasive tool for discriminating disease subtypes and predicting disease flare in clinical settings.
Article
Gastroenterology & Hepatology
Loren G. Rabinowitz, Haley M. Zylberberg, Jeong Yang, Stephanie Lauren Gold, Jaclyn Chesner, Jiayi Ji, Liangyuan Hu, Marla Dubinsky
Summary: This study identified factors associated with increased outpatient opioid use in IBD patients, including ulcerative colitis, ostomy placement during hospitalization, anxiety, and inpatient opioid exposure. Patients requiring >= 3 opioids had higher rates of unplanned IBD surgery, all-cause repeat hospitalization, and IBD-related repeat hospitalization in the year following hospitalization.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Adam Truong, Lucille Yao, Phillip R. Fleshner, Karen N. Zaghiyan
Summary: This study aimed to explore the possibility of perioperative opioid avoidance in patients undergoing colorectal surgery or those with inflammatory bowel disease (IBD). The research conducted a retrospective analysis of patients from two prospective studies and found that early postoperative opioid avoidance is feasible in a limited number of IBD patients after colorectal surgery.
COLORECTAL DISEASE
(2023)
Review
Chemistry, Medicinal
Dandan Liu, Varma Saikam, Katie A. Skrada, Didier Merlin, Suri S. Iyer
Summary: Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract, which can be diagnosed through endoscopy and biopsy. However, these methods are expensive and invasive, so alternative noninvasive biomarkers are being explored for disease management and prognosis.
MEDICINAL RESEARCH REVIEWS
(2022)
Review
Gastroenterology & Hepatology
Anna M. Buchner, Yecheskel Schneider, Gary R. Lichtenstein
Summary: Biological therapy targeting tumor necrosis factor-alpha has become crucial in treating patients with inflammatory bowel disease, but high costs limit accessibility. Biosimilars offer the potential to reduce expenditures and increase availability, providing more options for patients.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Mika Nakayama, Yuki Ozato, Yoshiko Tsuji, Yasuko Arao, Chihiro Otsuka, Yumiko Hamano, Genzo Sumi, Ken Ofusa, Shizuka Uchida, Andrea Vecchione, Hideshi Ishii
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by damage to the intestinal mucosa. Recent studies have shown the involvement of RNA modifications in the specific pathogenesis of IBD. RNA modification-targeting reagents have shown promising outcomes in treating colitis. Understanding RNA modifications in IBD could contribute to early diagnosis, disease monitoring, and innovative therapeutic approaches.
Article
Rheumatology
Clare Harris, J. R. Fraser Cummings
Summary: Primary non-response and secondary loss of response are still significant issues with current treatment options for inflammatory bowel disease, highlighting the need for new therapeutic choices. As our understanding of IBD pathogenesis advances, new therapeutic targets are being identified.
Review
Medicine, General & Internal
Elizabeth A. A. Spencer, Manasi Agrawal, Tine Jess
Summary: This article reviews the available predictors of outcomes in IBD patient and emphasizes the importance of global collaborative efforts and tools to support the clinical use of these prognostication tools.
FRONTIERS IN MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Brigida Barberio, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: This study conducted a network meta-analysis to compare the relative efficacy of various biological therapies and small molecules in the treatment of luminal Crohn's disease. The results showed differences in the effectiveness of different drugs in inducing and maintaining clinical remission, and previous exposure to biologics also had an impact on treatment outcomes.
Letter
Gastroenterology & Hepatology
Conchubhair Winters, Alexander Charles Ford
Review
Gastroenterology & Hepatology
Shahida Din, Christian P. Selinger, Christopher J. Black, Alexander C. Ford
Summary: A network meta-analysis was conducted to examine the risk of Herpes zoster infection associated with biologics and small molecules used to treat inflammatory bowel disease (IBD). The results showed that Janus kinase inhibitors, particularly tofacitinib, were most likely to increase the risk of Herpes zoster infection, and the risk increased with higher doses.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Vivek C. Goodoory, Elspeth A. Guthrie, Cho Ee Ng, Christopher J. Black, Alexander C. Ford
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Vivek C. Goodoory, Cho E. Ng, Christopher J. Black, Alexander C. Ford
Summary: This article is associated with Goodoory et al papers. Click the link to access these articles.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Alexander C. Ford, Colin W. Howden
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: The study suggests that diagnosing IBS according to the Rome IV criteria and conducting limited investigation is safe and durable. Among IBS patients, although 1 in 6 were referred again due to gastrointestinal symptoms, missed organic gastrointestinal disease occurred in only 1% of patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Maria rosa Ingrosso, Christopher j. Black, Alexander c. Ford
Article
Gastroenterology & Hepatology
Christy Riggott, Keeley M. Fairbrass, Christopher J. Black, David J. Gracie, Alexander C. Ford
Summary: Using latent class analysis, this study identified novel clusters of patients with inflammatory bowel disease (IBD) and found that patients with higher gastrointestinal and psychological symptoms were at a higher risk of adverse disease outcomes and were also high-volume users of healthcare.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Gastroenterology & Hepatology
Vivek C. Goodoory, Mais Khasawneh, Christopher J. Black, Eamonn M. M. Quigley, Paul Moayyedi, Alexander C. Ford
Summary: This article conducted a meta-analysis to study the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). The study found that certain combinations of probiotics or strains may be beneficial for IBS, but the certainty of the evidence was low.
Review
Gastroenterology & Hepatology
Pierfrancesco Visaggi, Brigida Barberio, Giulio Del Corso, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford, Edoardo Savarino
Summary: A network meta-analysis was conducted to compare the efficacy of different drugs for active eosinophilic esophagitis (EoE). The results showed that most available drugs were more effective than placebo in treating EoE. However, significant heterogeneity among the trials hindered the establishment of a solid therapeutic hierarchy.
Article
Gastroenterology & Hepatology
Brigida Barberio, Keeley M. Fairbrass, David J. Gracie, Alexander C. Ford
Summary: In this 12-month longitudinal study, one-third of patients with IBD reported presence of Rome III IBS-type symptoms at any point in time. Reporting such symptoms was associated with significant impacts on psychological health and/or quality of life.
NEUROGASTROENTEROLOGY AND MOTILITY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford